Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Rhea-AI Summary

Scinai Immunotherapeutics (Nasdaq: SCNI) said it received a Nasdaq written notice dated March 12, 2026, for noncompliance with the Nasdaq Capital Market minimum $1.00 bid price rule after ADSs closed below $1.00 for 30 consecutive business days.

The notice does not affect current listing or trading and provides an initial 180-calendar-day compliance period through September 8, 2026 to regain the $1.00 minimum by achieving at least ten consecutive business days at or above $1.00. The company said it will monitor the ADS closing price and evaluate options to regain compliance.

Positive

• Nasdaq listing and trading remain unaffected immediately
• Company granted a 180-day compliance period until Sept 8, 2026

Negative

• ADS closing bid was below $1.00 for 30 consecutive business days
• Risk of delisting if ADSs fail to reach $1.00 for 10 consecutive business days

Key Figures

Minimum bid price: $1.00 per share Noncompliance period: 30 consecutive business days Initial compliance period: 180 calendar days +3 more

6 metrics

Minimum bid price $1.00 per share Nasdaq Capital Market Listing Rule 5550(a)(2) requirement

Noncompliance period 30 consecutive business days Closing bid below $1.00 threshold

Initial compliance period 180 calendar days Time granted to regain minimum bid compliance

Compliance deadline September 8, 2026 End of initial Nasdaq compliance period

Required compliant days Ten consecutive business days Minimum time bid must be at or above $1.00

Nasdaq notice date March 12, 2026 Date of written notification from Nasdaq

Market Reality Check

Price: $0.7104 Vol: Volume 3,077 is far below...

low vol

$0.7104 Last Close

Volume Volume 3,077 is far below 20-day average of 51,664 (relative volume 0.06). low

Technical Price $0.7104 is trading below 200-day MA at $1.40, near the 52-week low of $0.613 and well under the 52-week high of $6.18.

Peers on Argus

SCNI was up 6.56% with very light volume, while only one biotech peer in the mom...

1 Up

SCNI was up 6.56% with very light volume, while only one biotech peer in the momentum scanner (INDP) moved in the same direction, up 5.139999836683273%. Other sector peers showed modest gains or flat moves, so the action appears stock-specific rather than a broad biotech rotation.

Historical Context

5 past events · Latest: Mar 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	PC111 grant update	Positive	-4.3%	Second amendment to PinCell option and revised €12m non-dilutive FENG application.
Feb 25	IIA grant support	Positive	+5.9%	Expanded Israel Innovation Authority support for robotic aseptic fill & finish platform.
Feb 17	Recipharm acquisition	Positive	+2.9%	Completion of Recipharm Israel acquisition and long-term strategic collaboration agreement.
Jan 07	Industry roundtable role	Neutral	-3.2%	CEO to co-lead biopharma manufacturing roundtable at HealthIL Week 2026.
Dec 02	Nine-month 2025 results	Neutral	+3.0%	Higher CDMO revenue alongside ongoing net loss and mixed grant outcomes.

Pattern Detected

Recent news has included several operational and funding positives, with mixed price reactions and one notable selloff on a funding-related update.

Recent Company History

Over the last six months, Scinai has reported expanding CDMO operations, grant support, and corporate developments. Highlights include a Recipharm Israel acquisition and collaboration, expanded Israel Innovation Authority backing, and nine-month 2025 financials showing higher CDMO-driven revenue but continued net loss. A revised non-dilutive FENG application for PC111 followed an earlier grant setback. Against this backdrop, the Nasdaq minimum bid price notice highlights listing-risk pressure on a stock already trading far below its 52-week high and under its 200-day MA.

Market Pulse Summary

This announcement details Nasdaq’s notification that Scinai’s ADSs failed to meet the $1.00 minimum ...

Analysis

This announcement details Nasdaq’s notification that Scinai’s ADSs failed to meet the $1.00 minimum bid price for 30 consecutive business days and outlines a 180-day window, until September 8, 2026, to regain compliance. In context of recent CDMO expansion, grants, and mixed financial performance, the key issues are whether the company maintains its Nasdaq listing, addresses the low share price, and continues advancing operational milestones that previously influenced trading after news events.

Key Terms

nasdaq capital market, minimum bid price requirement, american depositary shares, ads

4 terms

nasdaq capital market financial

"the listing or trading of the ADSs on the Nasdaq Capital Market."

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

minimum bid price requirement regulatory

"not in compliance with the Nasdaq Capital Market's minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

american depositary shares financial

"because the closing bid price of the American Depositary Shares ("ADSs") was below"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ads financial

"the closing bid price of the American Depositary Shares ("ADSs") was below $1.00"

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

AI-generated analysis. Not financial advice.

JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days.

The notification has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until September 8, 2026, to regain compliance with the minimum bid price requirement. If at any time during this period the closing bid price of the ADSs is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.

The Company will continue to monitor the closing bid price of its ADSs and evaluate available options to regain compliance with the Nasdaq minimum bid price requirement.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.

Company website: www.scinai.com

Company Contacts

Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the Company's ability to regain compliance with the Nasdaq minimum bid price requirement and the Company's evaluation of available options to achieve such compliance. Words such as "expects," "intends," "plans," "believes," "may," "will," "anticipates," "estimates," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, market conditions affecting the trading price of the American Depositary Shares and the Company's ability to meet the continued listing requirements of The Nasdaq Capital Market. More detailed information regarding these and other risks and uncertainties is included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on May 7, 2025, and in the Company's subsequent filings with the SEC.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.

Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-receives-nasdaq-notification-regarding-minimum-bid-price-302714995.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What did Scinai (SCNI) disclose about Nasdaq noncompliance on March 16, 2026?

Scinai disclosed it received a Nasdaq notice for failure to meet the $1.00 bid rule. According to the company, ADSs closed below $1.00 for 30 consecutive business days, triggering the Nasdaq Listing Qualifications Department notification on March 12, 2026.

Does the Nasdaq notice for SCNI stop trading of the ADSs immediately?

No, trading of SCNI ADSs is not suspended or halted by the notice. According to the company, the notification has no immediate effect on listing or trading and only starts a compliance period to regain the minimum bid price.

How long does Scinai (SCNI) have to regain Nasdaq compliance and what is the deadline?

Scinai has an initial 180-calendar-day compliance period to regain the $1.00 minimum bid price. According to the company, the deadline for this period is September 8, 2026, unless earlier compliance is achieved.

What must SCNI ADSs achieve to satisfy Nasdaq during the compliance period?

The ADSs must close at or above $1.00 for a minimum of ten consecutive business days. According to the company, Nasdaq will provide written confirmation once the ADSs meet that ten-day closing requirement.

What actions did Scinai (SCNI) say it will take after receiving Nasdaq's notice?

The company said it will monitor the ADS closing price and evaluate available options to regain compliance. According to the company, management will continue assessing measures to restore the ADS price to meet Nasdaq requirements.